Leukemia disease burden impacts response with CAR T-cell therapy – Healio
|
Leukemia disease burden impacts response with CAR T-cell therapy
Healio Adults with relapsed B-cell acute lymphoblastic leukemia who received CD19-28z chimeric antigen receptor cells had an 83% complete remission rate and a median survival of nearly 13 months, according to long-term follow-up of a phase 1 study published … |
